Skip to main content

Advertisement

Fig. 1 | Diabetology & Metabolic Syndrome

Fig. 1

From: Hypoadiponectinemia and the presence of metabolic syndrome in patients with chronic kidney disease: results from the KNOW-CKD study

Fig. 1

Crude prevalence rates of MS in the 20 groups, based on the combination of CKD stages and quartilized APN levels. Cross-categorization was performed based on the combination of CKD stages and quartilized APN category. Crude prevalence rates of MS were higher according to increased APN levels in CKD stage 1 [Q1 vs. Q4, 21 (45.7%) vs. 2 (4.3%)], stage 2 [47 (51.1%) vs. 6 (6.5%)], and stage 3 [80 (35.4%) vs. 32 (14.2%)] groups, but these correlations were blunted in stage 4. Furthermore, in stage 5 patients, group with the highest APN level had the most number of subjects diagnosed with metabolic syndrome [5 (8.6%) vs. 24 (41.4%)]. MS metabolic syndrome, CKD chronic kidney disease, APN adiponectin

Back to article page